Single-Photon Emission Computed Tomography (SPECT) Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization (SEEtoTREAT)

Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Observational
SUMMARY

The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (\ 20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223

• Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617

• \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol

• Age \> 18 years

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

• Histologic confirmation of malignancy

Locations
United States
Maryland
Johns Hopkins University
RECRUITING
Baltimore
Contact Information
Primary
Ana Kiess
akiess1@jhmi.edu
443-287-7528
Backup
Ryan Manuel
rmanuel5@jhmi.edu
410-955-4261
Time Frame
Start Date: 2025-02-03
Estimated Completion Date: 2029-08
Participants
Target number of participants: 80
Treatments
Cohort A
Patients with advanced prostate cancer planning to undergo treatment with Radium-223
Cohort B
Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617
Related Therapeutic Areas
Sponsors
Collaborators: National Cancer Institute (NCI)
Leads: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

This content was sourced from clinicaltrials.gov